Current Situation of Pediatric Clinical Trials in China: Focus on Trials for Drug Marketing Application and Administrative Approval

Overview

Journal BMC Pediatr

Publisher Biomed Central

Specialty Pediatrics

Date 2022 Mar 19

PMID 35303815

Authors

Lin Song

Yuntao Jia

Sujuan Ran

Bin Li

Jin Xu

Bennian Huo

Nange Yin

Maolin Ai

Yao Liu

Affiliations

Soon will be listed here.

Abstract

Background: Research and development of pediatric drug faces many difficulties and pediatric clinical trials remain a challenge. Since 2011, a series of measures have been taken to encourage research, development of drugs for pediatric patients in China. In this study, we analyzed pediatric clinical trials conducted in China to provide reference for research and development of pediatric drugs and formulation of relevant policies.

Methods: We conducted a cross-sectional observational study of pediatric trials registered in the Drug Trial Registration and Information Publication Platform before Oct. 31, 2021. All trials that recruited children (under 18 years old as defined in China) were retrieved and general characteristics of the trials and the research drugs were extracted and analyzed. The data were extracted and statistically analyzed by excel 2010 and SPSS 22.0, respectively.

Results: There were 588 registered pediatric clinical trials, which accounted for 3.94% of the total registered trials. The overall average annual growth rate of the number of trials from 2013 to 2020 was 14.47% (P < 0.01). Of the 588 trials included, there were 312 trials (53.06%) with only children as subjects, 127 trials (21.60%) with research drugs only for children use, and the median of target subject number was 320 with the range of 8 to 600,000. The sponsors and the principal investigators were mainly located in the eastern and northern China. 325 trials were vaccine trials, and the dosage form was mainly injection. There were 98 non-vaccine biological product trials (mainly injections), 135 chemical compound drug trials (mainly tablets), 30 traditional Chinese medicine/natural drugs (mainly granules). Indications of the non-vaccine drugs were mainly diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism.

Conclusion: The number of pediatric clinical trials in China has increased these years. To further promote pediatric clinical trials and motivate pediatric appropriate drug marketing application and administrative approval, conducting large pediatric clinical trials, further development of dosage forms suitable for children with special attention to neonates and prematurity, and improving uneven geographical distribution of sponsors and researchers are the current challenges.

Citing Articles

Paediatric Drug Development in China: Current Status and Future Prospects.

Song L, Zhang N, Jiang T, Jia Y, Liu Y Paediatr Drugs. 2024; 26(5):555-563.

PMID: 38837008 DOI: 10.1007/s40272-024-00636-8.

Quality assessment of paediatric randomized controlled trials published in China from 1999 to 2022: a cross-sectional study.

Huo B, Xu S, Liu Y, Su L, Jia Y, Ai M BMC Pediatr. 2024; 24(1):364.

PMID: 38802810 PMC: 11129423. DOI: 10.1186/s12887-024-04839-3.

Evaluation of marketing authorization and labels of medicines in 2021 WHO Model List of Essential Medicines for Children in China, the Russian Federation and Brazil.

Li C, Cheng L, Zhang X, Zhang L, Yan J Health Res Policy Syst. 2024; 22(1):33.

PMID: 38443935 PMC: 10913573. DOI: 10.1186/s12961-024-01117-7.

Off-Label Prescribing in Pediatric Population-Literature Review for 2012-2022.

Petkova V, Georgieva D, Dimitrov M, Nikolova I Pharmaceutics. 2023; 15(12).

PMID: 38139994 PMC: 10747118. DOI: 10.3390/pharmaceutics15122652.

Changes in Drug Clinical Trials of Thyroid Diseases in China, 2009-2022.

Li C, Hao J, Wang C, Yang J, Zheng Y, Zhang K Drug Des Devel Ther. 2023; 17:2315-2324.

PMID: 37559911 PMC: 10407876. DOI: 10.2147/DDDT.S409617.

References

Pratico A, Longo L, Mansueto S, Gozzo L, Barberi I, Tiralongo V . Off-Label Use of Drugs and Adverse Drug Reactions in Pediatric Units: A Prospective, Multicenter Study. Curr Drug Saf. 2018; 13(3):200-207. DOI: 10.2174/1574886313666180619120406. View

Jones C, Safferman M, Adams A, Platts-Mills T . Discrepancies between ClinicalTrials.gov recruitment status and actual trial status: a cross-sectional analysis. BMJ Open. 2017; 7(10):e017719. PMC: 5652524. DOI: 10.1136/bmjopen-2017-017719. View

Beleck A, Nachman S . Understanding Pediatric Drug Lag Time: Review of Selected Drug Package Inserts. J Pediatric Infect Dis Soc. 2020; 10(4):509-513. DOI: 10.1093/jpids/piaa136. View

Ueyama E, Kaneko M, Narukawa M . Analysis of Pediatric Drug Approval Lag in Japan. Ther Innov Regul Sci. 2020; 55(2):336-345. DOI: 10.1007/s43441-020-00218-z. View

Lagler F, Hirschfeld S, Kindblom J . Challenges in clinical trials for children and young people. Arch Dis Child. 2020; 106(4):321-325. DOI: 10.1136/archdischild-2019-318676. View

Zhang Y, Huang L, Zhou X, Zhang X, Ke Z, Wang Z . Characteristics and Workload of Pediatricians in China. Pediatrics. 2019; 144(1). DOI: 10.1542/peds.2018-3532. View

England A, Wade K, Smith P, Berezny K, Laughon M . Optimizing operational efficiencies in early phase trials: The Pediatric Trials Network experience. Contemp Clin Trials. 2016; 47:376-82. PMC: 4997801. DOI: 10.1016/j.cct.2016.03.002. View

Joret-Descout P, Prot-Labarthe S, Brion F, Bataille J, Hartmann J, Bourdon O . Off-label and unlicensed utilisation of medicines in a French paediatric hospital. Int J Clin Pharm. 2015; 37(6):1222-7. DOI: 10.1007/s11096-015-0191-3. View

Cho S, Serghiou S, Ioannidis J, Klassen T, Contopoulos-Ioannidis D . Large Pediatric Randomized Clinical Trials in ClinicalTrials.gov. Pediatrics. 2021; 148(3). DOI: 10.1542/peds.2020-049771. View

10.

Zhong Y, Zhang X, Zhou L, Li L, Zhang T . Updated analysis of pediatric clinical studies registered in ClinicalTrials.gov, 2008-2019. BMC Pediatr. 2021; 21(1):212. PMC: 8086350. DOI: 10.1186/s12887-021-02658-4. View

11.

delMoral-Sanchez J, Gonzalez-Alvarez I, Gonzalez-Alvarez M, Navarro-Ruiz A, Bermejo M . Availability of Authorizations from EMA and FDA for Age-Appropriate Medicines Contained in the WHO Essential Medicines List for Children 2019. Pharmaceutics. 2020; 12(4). PMC: 7238124. DOI: 10.3390/pharmaceutics12040316. View

12.

Wu W, Tang Z, Chen J, Gao Y . Pediatric drug development in China: Reforms and challenges. Pharmacol Res. 2019; 148:104412. DOI: 10.1016/j.phrs.2019.104412. View

13.

Greenberg R, Gamel B, Bloom D, Bradley J, Jafri H, Hinton D . Parents' perceived obstacles to pediatric clinical trial participation: Findings from the clinical trials transformation initiative. Contemp Clin Trials Commun. 2018; 9:33-39. PMC: 5898566. DOI: 10.1016/j.conctc.2017.11.005. View

14.

Mfoafo K, Omidian M, Bertol C, Omidi Y, Omidian H . Neonatal and pediatric oral drug delivery: Hopes and hurdles. Int J Pharm. 2021; 597:120296. DOI: 10.1016/j.ijpharm.2021.120296. View

15.

Tsukamoto K, Carroll K, Onishi T, Matsumaru N, Brasseur D, Nakamura H . Improvement of Pediatric Drug Development: Regulatory and Practical Frameworks. Clin Ther. 2016; 38(3):574-81. DOI: 10.1016/j.clinthera.2016.01.012. View

16.

Corny J, Bailey B, Lebel D, Bussieres J . Unlicensed and off-label drug use in paediatrics in a mother-child tertiary care hospital. Paediatr Child Health. 2016; 21(2):83-7. PMC: 4807801. DOI: 10.1093/pch/21.2.83. View

17.

Weiss E, Olszewski A, Guttmann K, Magnus B, Li S, Shah A . Parental Factors Associated With the Decision to Participate in a Neonatal Clinical Trial. JAMA Netw Open. 2021; 4(1):e2032106. PMC: 7804922. DOI: 10.1001/jamanetworkopen.2020.32106. View

18.

Yen E, Davis J, Milne C . Impact of Regulatory Incentive Programs on the Future of Pediatric Drug Development. Ther Innov Regul Sci. 2019; 53(5):609-614. DOI: 10.1177/2168479019837522. View

19.

Knopf H, Wolf I, Sarganas G, Zhuang W, Rascher W, Neubert A . Off-label medicine use in children and adolescents: results of a population-based study in Germany. BMC Public Health. 2013; 13:631. PMC: 3706213. DOI: 10.1186/1471-2458-13-631. View

20.

Eguale T, Buckeridge D, Verma A, Winslade N, Benedetti A, Hanley J . Association of Off-label Drug Use and Adverse Drug Events in an Adult Population. JAMA Intern Med. 2015; 176(1):55-63. DOI: 10.1001/jamainternmed.2015.6058. View